Linking metabolic reprogramming to therapy resistance in cancer

Andrea Morandi, Stefano Indraccolo

Research output: Contribution to journalReview articlepeer-review


Metabolic rearrangements are essential to satisfy the different requirements of cancer cells during tumorigenesis and recent studies have highlighted a role for such metabolic reprogramming in response and adaptation to therapies. However, therapy-resistant experimental models have been described to be either glycolysis-dependent or OXPHOS-addicted. Here we discuss the recent literature on metabolic reprogramming of cancer in therapy resistance with a plausible explanation of the observed differences which collectively indicate that dis-regulated metabolic pathways could be considered potential therapeutic targets in tumors resistant to conventional therapy.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Issue number1
Publication statusPublished - Aug 1 2017


  • Metabolic reprogramming
  • Therapy resistance
  • Warburg metabolism

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research


Dive into the research topics of 'Linking metabolic reprogramming to therapy resistance in cancer'. Together they form a unique fingerprint.

Cite this